10/30/2023 0 Comments Metoprolol succinate erLowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Metoprolol succinate is indicated for the treatment of hypertension, to lower blood pressure. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol succinate extended-release tablet therapy abruptly even in patients treated only for hypertension (5.1). Warn patients against interruption or discontinuation of therapy without the physician’s advice. If angina markedly worsens or acute coronary insufficiency develops, metoprolol succinate extended-release tablet administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. When discontinuing chronically administered metoprolol succinate extended-release tablets, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of 1 - 2 weeks and the patient should be carefully monitored. (5.11)įULL PRESCRIBING INFORMATION: CONTENTS * WARNING: ISCHEMIC HEART DISEASE: 1 INDICATIONS AND USAGE 1.1 Hypertension 1.2 Angina Pectoris 1.3 Heart Failure 2 DOSAGE AND ADMINISTRATION 2.1 Hypertension 2.2 Angina Pectoris 2.3 Heart Failure 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Ischemic Heart Disease 5.2 Heart Failure 5.3 Bronchospastic Disease 5.4 Pheochromocytoma 5.5 Major Surgery 5.6 Diabetes and Hypoglycemia 5.7 Hepatic Impairment 5.8 Thyrotoxicosis 5.9 Anaphylactic Reaction 5.10 Peripheral Vascular Disease 5.11 Calcium Channel Blockers 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Post-Marketing Experience 6.3 Laboratory Test Findings 7 DRUG INTERACTIONS 7.1 Catecholamine Depleting Drugs 7.2 CYP2D6 Inhibitors 7.3 Digitalis, Clonidine, and Calcium Channel Blockers 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 8.7 Renal Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Angina Pectoris 14.2 Heart Failure 15 REFERENCES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listed.įollowing abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. Calcium Channel Blockers: Because of significant inotropic and chronotropic effects in patients treated with beta-blockers and calcium channel blockers of the verapamil and diltiazem type, caution should be exercised in patients treated with these agents concomitantly.Peripheral Vascular Disease: Can aggravate symptoms of arterial insufficiency.Anaphylactic Reactions: Patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm. Patients with Hepatic Impairment: (5.7).Diabetes and Hypoglycemia: May mask tachycardia occurring with hypoglycemia.Do not routinely withdraw chronic beta blocker therapy prior to surgery.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |